Topic:

Venture Capital

Latest Headlines

Latest Headlines

Biotech boom drives blockbuster VC investments in Boston, San Francisco

The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the numbers for 2014. And the boom in venture investing looks set to continue well into 2015.

Lux Capital raises $350M to expand its startup portfolio

Lux Capital, a New York venture investor, put together a $350 million fourth fund, cash that will help bankroll startups in energy, technology and biotech.

Japan's Daiwa establishes major biotech fund for home and Taiwan

SINGAPORE-- A Japan-based securities firm said it has established the nation's largest fund in the biotech field, seeding it with $83.6 million to support startup biotech companies at home and in Taiwan.

NeuroVive pockets $3M on road to Taiwan IPO

NeuroVive Pharmaceutical has raised $3.3 million (€2.9 million) from Taiwanese investors to finance early aspects of its Asian expansion. The fundraising moves NeuroVive a step closer to realizing its plan to list its subsidiary on the Taiwan stock exchange.

Vaxxas banks $20M for its needle-free injection platform

Biotech upstart Vaxxas raised $20 million in the first close of its B round, cash that'll help the biotech develop a needle-free technology for vaccinations.

Woodford readies a $300M wager on struggling U.K. biotech sector

LONDON-- High-profile British fund manager Neil Woodford rolled out plans to raise about $300 million for an investment trust that will bet heavily on the U.K.'s struggling biotech sector.

Armetheon raises $24M to get its anticoagulant into Phase III

Menlo Park, CA's Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market.

G1 banks $33M to cut in on a blockbuster oncology race

North Carolina's G1 Therapeutics hauled in $33 million to advance a headline-grabbing approach to cancer treatment, helping the biotech hit the gas in a space otherwise dominated by Big Pharma.

Third Rock starts a $45M Revolution to soup up natural remedies

Revolution Medicines is developing technology it believes can do evolution one better, improving on naturally occurring compounds to transform promising but raw molecules into discrete drug candidates. And, with the help of $45 million from Third Rock Ventures, the biotech is first setting its sites on a pedigreed antifungal therapy.

Famed investor Mellon plans £100M fund for small biotechs

Jim Mellon wants to put his theory that British and European biotechs are undervalued to the test. The famed investor is trying to raise up to £100 million ($150 million) for a new fund dedicated to small biotechs in the United Kingdom and the rest of Europe.